Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

This article is a Letter to the Editor discussing rebound effects associated with JAK inhibitor use in treating alopecia areata and reports no new clinical results.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.